Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved GSK’s (GSK.L) oral treatment for gonorrhea, a common sexually transmitted infection.
The health regulator approved the drug, Blujepa, chemically known as gepotidacin, as an oral option for the treatment of uncomplicated urogenital gonorrhea in patients 12 years of age and older.
Gonorrhea, caused by a bacteria called neisseria gonorrhoeae, if left untreated or inadequately treated, can lead to infertility and other sexual and reproductive health complications.
The infection, which affects both men and women, is treatable and curable with antibiotics.

The U.S. FDA has approved GSK's oral drug, Blujepa (gepotidacin), for treating uncomplicated urogenital gonorrhea in patients aged 12 and older. Gonorrhea, a common sexually transmitted infection caused by neisseria gonorrhoeae, can lead to infertility and other health issues if untreated. The approval provides a new oral treatment option for this condition.

US FDA approves GSK's oral treatment for gonorrhea